Japan Atherosclerosis Society Cohort Study

Japan Atherosclerosis Society Cohort Study - JAS COHORT STUDY

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000018747

Enrollment

1500

Registered

2015-09-01

Start date

2015-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dyslipidemia

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Participants diagnosed as dyslipidemia by the JAS Guidelines for the Diagnosis and Prevention of Atherosclerotic Cardiovascular Diseases in Japan-2012 Version and followed and treated at out-patient clinic including diet therapy 1.Aged 40-74 years 2.Either gender 3.No history of cardiovascular disease

Exclusion criteria

Exclusion criteria: 1.Participants with familiar hypercholesterolemia, familial type III hyperlipidemia, and primary hyperchylomicronemia 2.Past history of stroke 3.Participants who are pregnant or lactating or intend to become pregnant 4.Participants with liver cirrhosis 5.Participants who were diagnosed as hyperthyroidism or hypothyroidism or stable at least 3 months by the treatment before entry 6.Participants who have experienced major surgery within the last 30 days 7.Participants who are currently receiving with oral retinoid agent for acne or psoriasis, systemic corticosteroids, or cyclosporine 8.Participants treated with anti-obesity drugs within the last 3 months 9.Participants who participated in the clinical trial or have been administed any investigational drug within the past 3 months, or the medical equipment 10.Participants who have received or a plan for a bariatric surgery for weight loss (gastric bypass, etc.) 11.Participants who are found to be HIV seropositive 12.Participants who have cancer, except for receiving the appropriate treatment for the localized basal cell skin cancer or mucosa in cervical cancer, or a history of cancer within the past 5 years 13.Participants with geographic elements or social element to limit the participation during the study period (including a transfer), or it is to be expected 14.Participants who are inadequate to enroll the study determined by the research doctor

Design outcomes

Primary

Measure	Time frame
1.Survey of Dyslipidemia treatment agents and the achievement of the Lipid Management Target Level of management category in the JAS Guidelines for the Diagnosis and Prevention of Atherosclerotic Cardiovascular Diseases in Japan-2012 Version 2.Relationships among cardiovascular events, dyslipidemia treatment agents, and the achievement of the Lipid Management Target Level of management category in the JAS Guidelines for the Diagnosis and Prevention of Atherosclerotic Cardiovascular Diseases in Japan-2012 and subsequent version.	—

Measure

Time frame

1.Survey of Dyslipidemia treatment agents and the achievement of the Lipid Management Target Level of management category in the JAS Guidelines for the Diagnosis and Prevention of Atherosclerotic Cardiovascular Diseases in Japan-2012 Version 2.Relationships among cardiovascular events, dyslipidemia treatment agents, and the achievement of the Lipid Management Target Level of management category in the JAS Guidelines for the Diagnosis and Prevention of Atherosclerotic Cardiovascular Diseases in Japan-2012 and subsequent version.

—

Secondary

Measure	Time frame
Non-fatal myocardial infarction and unstable angina Non-fatal stroke Coronary intervention Atrial fibrillation Death of cardiovascular cause Death of non-cardiovascular cause	—

Countries

Japan

Contacts

Public ContactSeiji Umemoto

Japan Atherosclerosis Society JAS Cohort Study group

jascohort@j-athero.or.jp03-5802-7711

Outcome results